New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Renaissance Herbs Announces Tulsi Basil Extract, 2% Ursolic Acid

Renaissance Herbs is pleased to announce the development of a hydro/ethanolic extract of Tulsi Basil

Tulsi or “Holy” Basil has largely been overlooked in the West, despite being one of the most esteemed botanicals in Ayurvedic medicine. Traditionally, the leaves of Tulsi Basil have been used in the treatment of colds, cough, asthma, fevers, dyspepsia, liver disorders, and in the prevention of influenza (Jain and DeFilipps, 1991; Paton et al., 1999; Nadkarni, 1976). In placebo-controlled clinical studies, the herb is reported to provide benefits in the treatment of type 2 diabetes (Agarwal et al., 1996) and hypertension (Subbulakshmi and Sarvaiya, 1991). Other clinical studies have reported improvements in patients with tropical pulmonary eosinophilia (Sharma et al., 1987) and acute viral encephalitis (Das et Pharmacological studies on Tulsi Basil are numerous and increasing. Among them, animal studies using leaf extracts (administered orally) have shown the following activities: Immunostimulating (T cell populations and antibodies) (Godhwani et al., 1988), fever-reducing (Godhwani et al., 1987), paininhibiting (Khanna and Bhatia, 2003), anti-inflammatory (Godhwani et al., 1987).

Active constituents of Tulsi Basil include ursolic acid which is credited for a number of activities of particular importance to the herb. The anti-inflammatory activity of ursolic acid is well known and Renaissance Herbs, Inc. ( is an American company dedicated to the research and development of the finest and most innovative botanical health care products available today. Our 50,000 square foot factory and R & D Center in Bangalore, India provides manufacturers with potent, standardized botanical extracts backed by Good Manufacturing Practices. The company was founded in 1990 by Alex Moffett and maintains offices in Los Angeles, California; Bangkok,

• Agrawal P, et al (1996). Randomized placebo-controlled, single blind trial of Holy basil leaves in patients with noninsulindependent
• Das SK, et al (1983). Ocimum sanctum (tulsi) in the treatment of viral encephalitis (a preliminary clinical trial). Antiseptic.
• Godhwani A, et al (1988). Ocimum sanctum – a preliminary study evaluating its immunoregulatory profile in albino rats. J
• Godhwani A, et al (1987). Ocimum sanctum: An experimental study evaluating its anti-inflammatory, analgesic and
• Jain SK and DeFilipps RA (1991). Medicinal Plants of India. Vol. 1. Algonac, MI: Reference Publications: 372-3.
• Khanna N and Bhatia J (2003). Antinociceptive action of Ocimum sanctum (tulsi) in mice: Possible mechanisms involved. J
• Nadkarni AK (1976). Indian Materia Medica. Vol. 1. Bombay, India: Popular Prakashan: 865-7.
• Paton A, et al (1999). Ocimum — an overview of relationships and classification. In: Hiltunen R, Holm Y, eds. Basil: The
• Sharma R, et al (1987). Management of tropical pulmonary eosinophilia in children with Ayurvedic drugs. J Res Ed Indian
• Subbulakshmi G and Sarvaiya SR (1991). Hypotensive effect of Ocimum sanctum. Bombay Hosp J. 33:39-43.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.